Employees: 327
Size Ceribell (CBLL) is a United States Health Care company (Medical Specialties) with a market value of $995M, the 2236th largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.63 on 18 Nov 2026.
Performance Over six months the shares gained 41.6%, against -7.9% for the median peer and -2.2% for the United States market (cap-weighted) — 4th highest of 20 in its peer set.
Growth Revenue grew 31.3% over the last twelve months (peer median +10.2%); the operating margin is -69.8% (peer median 11.7%).
Valuation It trades at 8.3× enterprise value to sales against a peer median of 3.5× (5th most expensive of 21).
Short interest Short interest is 5.0% of the free float (30 Oct 2026).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $109M | $89.1M | $65.4M | $45.2M | $25.9M |
| Revenue growth | — | +36% | +45% | +74% | — |
| Gross profit | $97.0M | $78.3M | $56.8M | $38.2M | $21.5M |
| EBITDA | -$74.8M | -$57.1M | -$38.6M | -$29.2M | -$35.5M |
| Net income | -$73.9M | -$53.4M | -$40.5M | -$29.5M | -$37.2M |
| Free cash flow | -$56.4M | -$41.7M | -$36.7M | -$30.1M | -$32.5M |
| Capital expenditure | $2.36M | $1.52M | $1.60M | $1.76M | $1.40M |
| Total debt | $21.6M | $22.3M | $22.0M | $14.2M | $18.2M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CBLL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.4% | -1.9% | 6th lowest of 21 |
| 6-month return | +41.6% | -7.9% | 4th highest of 20 |
| Distance from 52-week high | -11.3% | -28.9% | 5th highest of 21 |
| Revenue growth (TTM) | +31.3% | +10.2% | 2nd highest of 20 |
| Operating margin | -69.8% | 11.7% | 2nd lowest of 21 |
| EV / Sales | 8.3× | 3.5× | 5th most expensive of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | 8.3× | n/a | n/a |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 2.5× | 6.9% | -2.9% |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 3.1× | 10.7% | +12.9% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 4.7× | 4.9% | +10.4% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 0.9× | -4.0% | +3.5% |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | 11.1× | 50.8% | +8.6% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | 3.0× | n/a | n/a |
| Mani 7730.T | Japan | $965M | -7% | +10% | 30% | 3.9× | 3.3% | +13.9% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 2.7× | 7.7% | +12.1% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | 2.1× | 57.7% | +40.6% |
| JINS 3046.T | Japan | $963M | -8% | +14% | 10% | 1.3× | -6.1% | +11.7% |
| Safilo SFL.MI | Italy | $953M | +42% | -4% | 9% | 0.9× | 1.3% | +4.7% |
| Menicon 7780.T | Japan | $944M | +26% | +6% | 9% | 1.5× | n/a | n/a |
| L&C BIO 290650.KS | South Korea | $943M | -37% | +65% | 20% | 9.7× | 32.6% | +21.0% |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 11.1× | 18.5% | +21.5% |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | 4.3× | n/a | n/a |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | 85.0× | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 6.3× | 8.8% | +8.8% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 1.7× | 5.9% | +3.6% |
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 4.0× | -9.2% | +34.5% |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | 4.7× | n/a | n/a |